German price cuts loom for Novartis' Galvus and Merck's Januvia
This article was originally published in Scrip
Novartis and Merck could soon have to drop the prices of their DPP-4 inhibitors, vildagliptin and sitagliptin, in Germany if health technology appraisal bodies there remain less than impressed. The products are undergoing the first retrospective review under Germany's tough AMNOG pricing and reimbursement system and IQWiG, the Institute for Quality and Efficiency and Healthcare, has just released the preliminary findings.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.